Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. We also use them to share usage. B2Gold Declares Fourth Quarter 2023 Dividend. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. TH Stock Message Board for Investors. Theratechnologies reduces R&D head count to compensate for sales setback. By continuing to use our service, you agree to our use of cookies. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. Theratechnologies Inc. 26 +15. Data presented at AMCP Nexus 2023. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Conjugating the short peptide with various anti-cancer agents allows for. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. The Company currently commercializes two products in the field of HIV. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. According to 3 analysts, the average rating for THTX stock is "Buy. 25. Senior Director, Investor Relations. Stockhouse. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Cookies are used to offer you a better browsing experience and to. THERATECHNOLOGIES INC. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Learn why it. 54% and a negative trailing twelve-month return on equity of. GlobeNewswire. TH | October 13, 2022. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 04) earnings per share (EPS) for the quarter. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Theratechnologies Inc. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. ("Theratechnologies" or the "Company"). P. Theratechnologies Provides Details About R&D Day Webcast. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Stockhouse. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. TH | March 7, 2023. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A high-level overview of Theratechnologies Inc. TH | Complete Theratechnologies Inc. NEW YORK, Dec. Theratechnologies, Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. Non-Profit & Charitable Organizations · United States · <25 Employees. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Stockhouse. Last Reviewed: February 24, 2023. Forecast to breakeven in 2024 Jul 15. 22M. . Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Shares of Theratechnologies are up 4. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. We also use them to share usage. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. communications@theratech. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 69 to $1. com uses cookies on this site. FY2023 revenue guidance range set between $90 million and $95 million. stock news by MarketWatch. 4 million. By continuing to use our service, you agree to our use of cookies. Losses were -47. We also use them to share usage. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. Theratechnologies, Inc. 89 52. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. We also use them to share usage. MONTREAL, Aug. We currently market prescription products for people with HIV in the United States. 1M. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). This suggests a possible upside of 2,471. We also use them to share usage. 35 as of 10:41 a. T. First Quarter Fiscal 2022 Financial Results. 1300 (+9. Theratechnologies had a negative net margin of 36. (2013-04-03 | TSX:TH) Theratechnologies Inc. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. About SORT1+ Technology™ and TH1902. : Nasdaq Theratechnologies Inc. Statut du système de négociation. (“Theratechnologies”) with the Securities and Exchange Commission (the. - Cash, bonds and money market funds of US$22. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Stockhouse. THTX earnings call for the period ending February 29, 2020. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. The abstract and poster can be found on Theratechnologies’ website. Further. Stockhouse. com uses cookies on this site. (2013-04-03 | TSX:TH) Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. com uses cookies on this site. Theratechnologies Inc. 9 million, adjusted EBITDA of $2. com uses cookies on this site. Christian Marsolais, Ph. 2 million. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. . com uses cookies on this site. L. com uses cookies on this site. The price has fallen in 5 of the last 10 days. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Theratechnologies Appoints New Board Member. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Jan. Headquarters. com uses cookies on this site. However, only about 4% of the stocks on the OTC market fall into this category. znewcar1. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 65 per cent to C$1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Aug. com uses cookies on this site. ( THTX 3. m. (THTX) stock. 20% from a day low at $1. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Clinical-stage pharmaceutical company Theralase Technologies Inc. 4. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Currency in USD Follow 2W 10W 9M 1. com uses cookies on this site. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. B2Gold Declares Fourth Quarter 2023 Dividend. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. US Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Investor Relations. The financial results presented in this press release are taken from the. Investor Relations. 57%) Q1 2020 Earnings Call. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. Stockhouse. 00. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. W. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. MONTREAL, Dec. Cookies are used to offer you a better browsing experience and to analyze our traffic. Saint-Laurent, Canada. 514-336-7800. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. H. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. MONTREAL, Aug. Thank you. Stockhouse. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Dec. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. is an employee of TaiMed Biologics USA, Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. By continuing to use our service, you agree to our use of cookies. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Theratechnologies Inc. 72%. Stockhouse. In the United States, Trogarzo ® (ibalizumab. communications@theratech. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. - 2023 Q3 positive adjusted EBITDA to be. Theratechnologies inc. Stockhouse. MONTREAL, Oct. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. - Q3 2022 North American Revenue Growth of 19%. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. TH | September 26, 2023. TORONTO, Sept. This news release constitutes a "designated news release" for the purposes of. We also use them to share. 10% most volatile stocks in CA Market. Theratechnologies Appoints New Board Member. Theratechnologies Inc. 49%) At close: 04:00PM EST 1. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. During the last trading day the stock fluctuated 4. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Marsolais’ presentation will be available through. 08). (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing. By continuing to use our service, you agree to our use of cookies. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Katana shareholders will. com uses cookies on this site. 1-438. . (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Image source: The Motley Fool. Their average twelve-month price target is $36. Theratechnologies’ R&D staff is bearing the brunt of. 2% to $21. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. 86 million for the quarter. Further. 81 million for the quarter. We currently market prescription products for people with HIV in the United States. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Cookies are used to offer you a better browsing experience and to analyze our traffic. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. 9% more than in 2021. 16%. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Visit the TSX ETF Investor Centre to access our screener and comparison tool. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Once expert advice is considered, the Company. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Stockhouse. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . 28 $1. With the company starting 2023 with 8,725 employees, that’s an 11. During the last trading day the stock fluctuated 12. View real-time stock prices and stock quotes for a full financial overview. We currently market. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com uses cookies on this site. MONTREAL, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. We currently market prescription products for people with. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. 75. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. stock news by MarketWatch. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. com uses cookies on this site. com uses cookies on this site. $30. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 74M. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Cookies are used to offer you a better browsing experience and to analyze our traffic. Volume has increased on the last day along with the price, which is a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . m. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. We also use them to share usage. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. 33. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. . Further. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. By continuing to use our service, you agree to our use of cookies. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. MONTREAL, Oct. Stockhouse. Elif McDonald - Senior Director, Investor Relations. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. 9 million and US. (TH. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. The business had revenue of $27. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. was a. About Theratechnologies. . ET. com. 124. Theratechnologies. Register for your free account today at data. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. Montréal, Québec, Canada . com. Theratechnologies's earnings have been declining at an average annual rate of -35. FY2022 revenue. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. 617-356-1009. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. - Q3 2022 Consolidated. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. The webinar will also address system-level barriers and present real-world. 89 $2. 10% least volatile stocks in CA Market. acts as investment manager. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Cookies are used to offer you a better browsing experience and to analyze our traffic. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. MONTREAL, Sept. By Nick Paul Taylor Jul 12, 2023 8:57am. Theratechnologies inc. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. 1-514-336-7800. FAQ – Utilisateurs de TMX Argent NOUVEAU. com uses cookies on this site. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023.